前列腺癌检测风险计算器:一项系统综述
该系统综述检索2010年1月至2023年7月数据库,纳入140篇文章,识别96个预测活检检出临床显著前列腺癌的风险计算器,其中45个经外部验证,外部验证风险计算器的中位AUC范围为0.63至0.93。
要点
- 共识别96个风险计算器,45个经外部验证,28个在多个队列中验证。
- 外部验证的风险计算器中,17个基于临床因素,19个结合临床因素与MRI细节。
- 外部验证风险计算器的中位AUC范围为0.63至0.93。
核心结论
- 该系统综述全面分析了现有风险计算器、其使用情况及其在验证队列中的性能。
- 风险计算器持续证明其能够减轻早期检测相关的局限性,并已整合到现代实践和筛查试验中。
- 缺乏外部验证数据引发了对许多风险计算器的担忧,在评估特定风险计算器是否适用于目标人群时,必须考虑这一缺失。
研究设计与样本
- 系统综述,检索Medline ALL、Embase、Web of Science核心合集、Cochrane对照试验中心注册库和Google Scholar中2010年1月至2023年7月的出版物。
- 纳入标准包括系统综述、Meta分析和临床试验;排除涉及预先针对的高风险人群、已诊断前列腺癌患者或样本量小于50名男性的研究。
- 共识别6474篇文章,筛选摘要和全文后纳入140篇。
主要发现
- 共识别96个独特的风险计算器,其中45个经外部验证,28个在多个队列中验证。
- 外部验证的风险计算器中,17个基于临床因素,19个结合临床因素与MRI细节,4个仅基于血液生物标志物或联合临床因素,5个包括尿液生物标志物。
- 外部验证风险计算器的中位AUC范围为0.63至0.93。
关键数值与推荐
- 欧洲泌尿外科学会建议采用个体化风险适配方法,将风险计算器纳入前列腺癌检测路径。
- 外部验证风险计算器的中位AUC范围为0.63至0.93。
临床怎么用
- 风险计算器已整合到现代实践和筛查试验中。
- 在评估特定风险计算器是否适用于目标人群时,必须考虑其缺乏外部验证数据这一缺失。
局限性
- 缺乏外部验证数据引发了对许多风险计算器的担忧。
- 在评估特定风险计算器是否适用于目标人群时,必须考虑外部验证数据的缺失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PCa) (early) detection poses significant challenges, including unnecessary testing and the risk of potential overdiagnosis. The European Association of Urology therefore suggests an individual risk-adapted approach, incorporating risk calculators (RCs) into the PCa detection pathway. In the context of 'The PRostate Cancer Awareness and Initiative for Screening in the European Union' (PRAISE-U) project ( https://uroweb.org/praise-u ), we aim to provide an overview of the currently available clinical RCs applicable in an early PCa detection algorithm. METHODS: We performed a systematic review to identify RCs predicting detection of clinically significant PCa at biopsy. A search was performed in the databases Medline ALL, Embase, Web of Science Core Collection, Cochrane Central Register of Controlled Trials and Google Scholar for publications between January 2010 and July 2023. We retrieved relevant literature by using the terms "prostate cancer", "screening/diagnosis" and "predictive model". Inclusion criteria included systematic reviews, meta-analyses, and clinical trials. Exclusion criteria applied to studies involving pre-targeted high-risk populations, diagnosed PCa patients, or a sample sizes under 50 men. RESULTS: We identified 6474 articles, of which 140 were included after screening abstracts and full texts. In total, we identified 96 unique RCs. Among these, 45 underwent external validation, with 28 validated in multiple cohorts. Of the externally validated RCs, 17 are based on clinical factors, 19 incorporate clinical factors along with MRI details, 4 were based on blood biomarkers alone or in combination with clinical factors, and 5 included urinary biomarkers. The median AUC of externally validated RCs ranged from 0.63 to 0.93. CONCLUSIONS: This systematic review offers an extensive analysis of currently available RCs, their variable utilization, and performance within validation cohorts. RCs have consistently demonstrated their capacity to mitigate the limitations associated with early detection and have been integrated into modern practice and screening trials. Nevertheless, the lack of external validation data raises concerns about numerous RCs, and it is crucial to factor in this omission when evaluating whether a specific RC is applicable to one's target population.
引用
- Denijs FB, van Harten MJ, Meenderink JJL, et al. Risk calculators for the detection of prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2024. PMID: 38830997. doi:10.1038/s41391-024-00852-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。